Medical/Pharmaceuticals

Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA

HANGZHOU and SHAOXING, China, May 25, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab to treat patients with re...

2021-05-25 08:30 2742

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

SHANGHAI and HARTFORD, Conn., May 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and...

2021-05-25 08:00 3373

Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma

SAN FRANCISCO and SUZHOU, China, May 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dis...

2021-05-25 08:00 11243

SIRONA - The world's first and largest RCT comparing Sirolimus V/S Paclitaxel balloon for the treatment of Peripheral Arterial Disease progresses rapidly

JENA, Germany, May 25, 2021 /PRNewswire/ -- Concept Medical Inc., focused on vascular intervention drug delivery devices, releases status updates ofSIRONA Randomized Control Trial (RCT) which compares head-to-head,SIROlimus versus Paclitaxel Drug-Eluting BallooN...

2021-05-25 07:03 2950

Lifebit Awarded A Four-Year Contract for Hong Kong's Genome Project

Lifebit's precision medicine software will power Hong Kong's development of genomic medicine by supporting the Hong Kong Genome Institute to implement the first large-scale genome sequencing initiative, the Hong Kong Genome Project. The Project will empower medical professionals and researchers t...

2021-05-25 06:00 3073

Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing

VANCOUVER, British Columbia, May 24, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce thatCharles J. Dunton, MD, has joined BioVaxys as an Advisor to help provide additional scientific support for BVX-0918A,...

2021-05-24 20:00 6792

Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States

HONG KONG, May 24, 2021 /PRNewswire/ -- On May 24, 2021, Akeso, Inc. (HKEx: 9926.HK) announced that Penpulimab (research and development code: AK105), an PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical Limited (HKEx: 1177.HK), has submitted a Biologics Licens...

2021-05-24 18:17 2811

5.20 Infinitus Social Responsibility Day 2021 aims to improve public heath

GUANGZHOU, China, May 24, 2021 /PRNewswire/ -- On May 20, Infinitus (China) Company Ltd. organized the 3rd 5.20 Infinitus Social Responsibility Day with the theme of "Promoting Chinese Culture of Health Maintenance, Supporting the Healthy China Initiative" at the company's production base in Xinh...

2021-05-24 17:00 405

CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™

* A major step for introducing Convidecia™ to more countries and people in need for protection * Vaccine has been approved in China, Mexico, Pakistan, Hungary and Chile * Provides timely clinical protection for adults aged 18 and above, including those over 60 TIANJIN, China, May 24, 2021 /P...

2021-05-24 17:00 5998

Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis (IPF) shows promising result in early stage clinical test

* We confirmed the safety of 'DWN12088' and secured grounds for establishing treatment dosage * Confirming the potential as a treatment for IPF and planning to apply for Ph.2 within 2021 * 2nd ODD granted as treatment for systemic sclerosis from the US FDA SEOUL, South Korea, May 24, 2021 /...

2021-05-24 16:59 1569

Ko-Max to debut a new suction system with enhanced user interface

INCHEON, South Korea, May 24, 2021 /PRNewswire/ -- Aerosol Suction "Silence Series", Ko-Max's new, lighter suction system with better user interface than the conventional model is getting popular. Ko-Max announced that its Silence Series, released last month, is becoming popular in various secto...

2021-05-24 16:14 1474

Aiming for Zero Leprosy: 30th Anniversary of World Health Assembly Resolution and WHO Global Leprosy Strategy 2021-2030 Are Opportunities to Accelerate Efforts against the Disease

TOKYO, May 24, 2021 /PRNewswire/ -- Thirty years ago this month, the World Health Assembly (WHA) adopted a resolution to eliminate leprosy as a public health problem. Today, as the 74th WHA gets under way, WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa is urging countries not to o...

2021-05-24 15:00 1329

Luye Pharma's Innovative Alzheimer's Disease Therapy Rivastigmine Multi-Day Transdermal Patch Now Eligible for Marketing Authorization in Several EU Countries

MIESBACH, Germany and BASEL, Switzerland, May 24, 2021 /PRNewswire/ -- Luye Pharma Group today announced the successful completion of the Decentralised Registration Procedures (DCPs) for its Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD). With the end of procedure achieved on21 May 20...

2021-05-24 10:27 2907

Seegene introduces an exclusive diagnostic system for diagnosing COVID-19 variants at ECCMID

SEOUL, Korea, May 24, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a biotechnology firm specializing in molecular diagnostics has once again been recognized for its unique system for diagnosing COVID-19 variants at this year's European Congress of Clinical Microbiology, the ECCMID. Seegene's...

2021-05-24 09:58 1714

Poster to Highlight ENVASARC Pivotal Trial of Envafolimab (KN035) will be presented at the 2021 ASCO Annual Meeting

SUZHOU, China, May 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the study design of the ENVASARC pivotal trial in the U.S. of Envafolimab (KN035), a recombinant humanized PD-L1 single domain antibody independently invented by Alphamab Oncology, will be presented by A...

2021-05-24 08:54 5758

Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea

Novavax and SK bioscience reaffirm partnership during meeting with South Korean leaders GAITHERSBURG, Md., May 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-...

2021-05-23 00:39 9144

Ortho Clinical Diagnostics Simultaneously Launches First Quantitative COVID-19 IgG Spike Antibody Test As Well As A Nucleocapsid Antibody Test to Help Differentiate Cause of Antibody Response

- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of antibodies against SARS-CoV-2 - Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody t...

2021-05-22 05:22 9475

Recently Merged dMed and Clinipace Announce the Appointment of New Global COO

SHANGHAI and MORRISVILLE, N.C., May 21, 2021 /PRNewswire/ -- Following the recent merger announcement ofShanghai-based dMed Global and NC-based Clinipace Incorporated, the combined company today announced the appointment ofSimon Britton to the position of Chief Operating Officer (COO).  Britton w...

2021-05-21 20:00 5041

Blue Launches #WeSupport Campaign for Complimentary Post-Vaccination Protection

HONG KONG, May 21, 2021 /PRNewswire/ -- Blue, Hong Kong's first digital life insurer, launches the #WeSupport campaign to provide customers with extra free protection for post-vaccination. To safeguard customers and their families' health, and to ensure they can get vaccinated with assurance, eli...

2021-05-21 17:19 2589

/DISREGARD RELEASE: Seegene Inc./

We are advised by Seegene Inc. that journalists and other readers should disregard the news release, Seegene reports solid results in the first quarter of 2021 withKRW 351.8 billion, issued 12-May-2021 over PR Newswire....

2021-05-21 09:36 16284
1 ... 283284285286287288289 ... 397